- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05360602
Alpha Lipoic Acid Effect on No-Reflow Phenomenon
Evaluation of The Effect of Alpha Lipoic Acid Administration on Oxidative Stress Markers and Occurrence of No-Reflow Phenomenon in Post Myocardial Infarction Patients
Study Overview
Status
Conditions
Detailed Description
All (60) STEMI patients undergoing PCI presenting to the Cardiology department will be randomly assigned into one of 2 arms: 30 patients undergoing PCI who will receive standard of care for 1 week, the other 30 patients undergoing PCI will receive standard of care in addition to Alpha Lipoic Acid 600 mg daily for 1 week. IV Alpha Lipoic Acid 600 mg once daily will be administered prior to PCI then orally daily for 1 week after PCI.
Baseline evaluation included demographics and history taking. After obtaining the informed consent, information including age, weight, height, smoking state, and other diseases e.g. hypertension, diabetes, hyperlipidemias, etc. will be documented for each patient. Medication history in detail, as well as the background cardiovascular treatment, will be considered.
All patients will be followed up regularly during the hospital stay and after discharge, will be assessed for the occurrence of adverse cardiac events and occurrence of adverse effects from medications
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Omar Ragab Elsayed, BSc
- Phone Number: 00201011177942
- Email: omar.ragab@pharma.asu.edu.eg
Study Contact Backup
- Name: Lamiaa M El Wakeel, PhD
- Phone Number: 00201005201099
- Email: lamywak@yahoo.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female or male aged >18 and < 75 years
- STEMI patients undergoing PCI
Exclusion Criteria:
- Patients with a recent history of myocardial infarction (MI), a previous PCI or a previous coronary artery bypass graft
- A late presentation (>12 h), unsuccessful primary PCI (residual stenosis >50% in the culprit lesion after procedure)
- Pretreatment with thrombolytic or glycoprotein IIb/IIIa inhibitor therapy before primary PCI
- Infectious or inflammatory disease
- Severe liver or renal disease, (AST or ALT >3x ULN or Total bilirubin >2.5 x ULN), (CrCl < 60 ml/min (based on the Cockroft-Gault equation)
- Neoplasm, or hematological disorders
- Pregnant or breast-feeding patients
- Active participation in another clinical study
- Patients taking Alpha Lipoic Acid.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Control group
30 STEMI patients undergoing PCI who will receive standard of care for 1 week that will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
|
will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
Other Names:
|
Experimental: Test group
30 STEMI patients undergoing PCI who will receive the standard of care in addition to IV Alpha Lipoic Acid 600 mg before PCI then 600 mg orally for 1 week after PCI
|
Intravenous and oral administration of Alpha Lipoic Acid 600 mg plus the standard care for post-PCI MI which will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of No-Reflow phenomena
Time Frame: During 1 week post PCI
|
To study the effect of Alpha Lipoic Acid administration on the occurrence of No-Reflow phenomena in post-myocardial infarction patients
|
During 1 week post PCI
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of markers that reflect oxidative stress and inflammation.
Time Frame: Baseline and Day 7 post PCI
|
Measuring serum concentration of aldehyde dehydrogenase-2 (ALDH2) and paraoxonase-1 (PON-1).
ALDH2 reflects oxidative stress, paraoxonase-1 reflects oxidative stress and inflammation.
|
Baseline and Day 7 post PCI
|
Occurrence of MACE.
Time Frame: up to 4 weeks post PCI.
|
re-infarction, stroke, cardiovascular hospitalisation, and death.
|
up to 4 weeks post PCI.
|
Tolerability of Alpha Lipoic Acid administration
Time Frame: During 1 week post PCI
|
Occurrence of adverse drug effects
|
During 1 week post PCI
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ayman M Saleh, MD, Faculty of Medicine, Ain Shams University
- Study Director: Lamiaa M El Wakeel, PhD, Faculty of Pharmacy, Ain Shams University
- Study Director: Marwa Adel Ahmed, PhD, Faculty of Pharmacy, Ain Shams University
Publications and helpful links
General Publications
- Choudhary S. Association of syntax score with short-term outcomes among acute ST-elevation myocardial infarction patients undergoing primary PCI. Indian Heart J. 2017 Apr;69 Suppl 1(Suppl 1):S20-S23. doi: 10.1016/j.ihj.2016.08.002. Epub 2016 Aug 24.
- Mazhar J, Mashicharan M, Farshid A. Predictors and outcome of no-reflow post primary percutaneous coronary intervention for ST elevation myocardial infarction. Int J Cardiol Heart Vasc. 2015 Nov 6;10:8-12. doi: 10.1016/j.ijcha.2015.11.002. eCollection 2016 Mar.
- Kloner RA. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):244-50. doi: 10.1177/1074248411405990.
- Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA, Pache J, Alger P, Mehilli J, Schomig A, Kastrati A. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010 May 25;55(21):2383-9. doi: 10.1016/j.jacc.2009.12.054.
- Fearon IM, Faux SP. Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J Mol Cell Cardiol. 2009 Sep;47(3):372-81. doi: 10.1016/j.yjmcc.2009.05.013. Epub 2009 May 28. Erratum In: J Mol Cell Cardiol. 2009 Nov;47(5):748.
- Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998 Apr 15;101(8):1581-90. doi: 10.1172/JCI1649.
- Wang X, Yu Y, Ji L, Liang X, Zhang T, Hai CX. Alpha-lipoic acid protects against myocardial ischemia/reperfusion injury via multiple target effects. Food Chem Toxicol. 2011 Nov;49(11):2750-7. doi: 10.1016/j.fct.2011.07.065. Epub 2011 Aug 6.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NRF-123
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on No-Reflow Phenomenon
-
Hull University Teaching Hospitals NHS TrustCompletedSTEMI | No Reflow PhenomenonUnited Kingdom
-
Assiut UniversityNot yet recruiting
-
TC Erciyes UniversityCompleted
-
Universität Duisburg-EssenUnknownCoronary Heart Disease | Coronary Arteriosclerosis | No Reflow PhenomenonGermany
-
Instituto Nacional de Cardiologia Ignacio ChavezNot yet recruitingSTEMI | No-Reflow Phenomenon
-
Assiut UniversityRecruiting
-
First Hospital of China Medical UniversityAstraZenecaUnknownMyocardial Infarction | No-Reflow PhenomenonChina
-
Privolzhsky Research Medical UniversityCompletedMyocardial Infarction | No-Reflow PhenomenonRussian Federation
-
National Institute of Cardiovascular Diseases,...CompletedAcute Coronary Syndrome | No-Reflow Phenomenon | NormotensivePakistan
-
RenJi HospitalCompletedST Segment Elevation Myocardial Infarction | Coronary Slow Flow PhenomenonChina
Clinical Trials on The standard care for post-PCI MI
-
Helse Stavanger HFCompletedAcute Myocardial InfarctionNorway
-
Minneapolis Heart Institute FoundationNational Heart, Lung, and Blood Institute (NHLBI)CompletedAcute Myocardial InfarctionUnited States
-
Heinrich-Heine University, DuesseldorfAbiomed Inc.; Profil Clinical Trials Coordination GmbHRecruitingHigh-risk Percutaneous Coronary Intervention | Induced Acute Kidney InjuryGermany
-
Johns Hopkins UniversityNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingSudden Infant Death | Sudden Unexplained Infant DeathUnited States
-
Brigham and Women's HospitalCompletedOsteoarthritis | Degenerative Joint DiseaseUnited States
-
Virginia Commonwealth UniversityGuerbetWithdrawnCoronary Artery Disease | Acute Kidney Injury | Percutaneous Coronary InterventionUnited States
-
Jennifer WoyachJanssen Scientific Affairs, LLCCompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Monoclonal Gammopathy of Undetermined Significance | Myelodysplastic Syndrome | Aplastic Anemia | Symptomatic COVID-19 Infection Laboratory-Confirmed | Monoclonal B-Cell LymphocytosisUnited States
-
Milton S. Hershey Medical CenterRecruiting
-
Milton S. Hershey Medical CenterFour Diamonds Research Fund at Penn State Health Childrens HospitalRecruiting